Helkha Peredo-Pinto

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Topics

End Stage Renal Disease

Diffuse Large B Cell Lymphoma

Ejection Fraction

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)